Compare AbbVie Inc (ABBV) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Godaddy Inc — how do they compare? AbbVie Inc trades at $253.24 (market cap $449.91B), while Godaddy Inc trades at $87.94 (market cap $11.83B). The key difference: AbbVie Inc is far larger — about 38× Godaddy Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| ABBV | GDDY | |
|---|---|---|
Market Cap | $449.91B | $11.83B |
Sector | Health | Technology |
52-Week High | $261.07 | $177.04 |
52-Week Low | $184.85 | $75.07 |
Enterprise Value | $513.38B | $14.41B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
GoDaddy (GDDY) trades at $89.32, up 0.92% on the day, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company exhibits strong profitability with a 17.32% net income margin and consistent earnings beats, though revenue growth is moderating. Recent news highlights a securities class action investigation and optimism around AI resilience, with Q2 2026 results due July 30, 2026.
The stock presents a mixed outlook: analyst consensus is bullish with a $123 price target, but legal risks and high ROE from low equity base warrant caution. Upside hinges on execution amid competitive pressures, while any negative legal developments could pressure shares near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
